---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-25-000128"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:35:43.465052+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Immunovant Q1 net loss $120.6M; initiates two registrational trials for IMVT-1402

## Summary
- Cash of $598.9M provides runway through Graves' disease readout expected in 2027.
- Net loss $120.6M ($0.71/share) vs $87.2M ($0.60) in prior-year quarter.
- Initiated a second potentially registrational trial of IMVT-1402 in Graves' disease in June 2025.
- Initiated a potentially registrational trial of IMVT-1402 in Sjögren's disease in June 2025.
- Expects GD remission data from batoclimab proof-of-concept study at ATA meeting in September 2025.

## SEC filing metadata
- accession: 0001764013-25-000128
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000128/0001764013-25-000128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000128/imvt-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-25-000128
- JSON: https://secwatch.observer/filing/0001764013-25-000128.json
- Plain text: https://secwatch.observer/filing/0001764013-25-000128.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.